Abatacept was clinically applied in treating RA under the mechanism of action involves binding to CD80 and CD86 on antigen-presenting cells, thereby inhibiting T-cell activation through blocking the costimulatory interaction with CD28 on T cells. Here, CD86 is linked to rheumatoid arthritis.